CHAPTER 1 - MARKET SUMMARY
Market Overview
The Global Gait Trainer Market operates across manual supportive walkers, robotic and powered exoskeletons, treadmill-based systems, body-weight-support platforms and wearable or FES-enabled rehabilitation systems. Demand is anchored in neurological, orthopedic, pediatric and geriatric rehabilitation. In 2024, WHO estimated that 2.4 billion people globally lived with conditions potentially benefiting from rehabilitation, establishing a broad long-term patient funnel for mobility restoration technologies.
North America remains the largest commercial hub, representing approximately 37.8% of global market value in the pre-validated market model. Its importance reflects mature rehabilitation networks, high adoption of clinical robotics and concentrated supplier activity. The United States also anchors major participants including Ekso Bionics, Biodex, Rifton and Restorative Therapies, while CMS reimbursement reforms are improving the economics of selected personal powered exoskeletons.
Market Value
USD 392 million
2025
Dominant Region
North America
2025
Dominant Segment
Robotic / Exoskeleton Gait Trainers
fastest growing
Total Number of Players
200+
Future Outlook
The Global Gait Trainer Market is forecast to expand through the 2025-2032 period as hospitals, specialist rehabilitation centers and home-care channels adopt more advanced mobility systems. The market progresses from USD 392 Mn in 2025 toward an intermediate value of approximately USD 556 Mn in 2031. Its historical CAGR of 5.4% during 2020-2025 reflects recovery in rehabilitation capital expenditure and rising adoption of technology-enabled therapy. The forecast CAGR increases to 6.0%, supported by robotic systems, connected assessment tools, FES integration and reimbursement pathways that broaden access to premium devices.
By 2032, market value is projected to reach USD 589 Mn. Volume is expected to expand from approximately 46,966 units in 2025 to about 66,085 units in 2032, while blended revenue per unit rises as clinical robotics, software and higher-value service bundles capture more spending. The value CAGR therefore exceeds the modeled 5.0% volume CAGR. Asia-Pacific remains the primary geographic acceleration opportunity, while North America retains the largest value pool. For suppliers, the strongest profit-pool transition is toward integrated hardware, analytics, service contracts and reimbursable personal-use solutions rather than standalone manual equipment.
6.0%
Forecast CAGR
$589 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
5.4%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, robotics mix, installed base, reimbursement, margins, exits
Corporates
product roadmap, ASP, service revenue, channels, partnerships, localization
Government
rehabilitation access, reimbursement, workforce, procurement, standards, clinical capacity
Operators
utilization, therapist productivity, patient throughput, maintenance, training, outcomes
Financial institutions
equipment finance, reimbursement certainty, cash flow, capex, credit
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
The historical period reflects a transition from predominantly manual and clinic-centered systems toward higher-value instrumented and robotic rehabilitation. Modeled unit demand increased from about 37,700 devices in 2020 to 46,966 in 2025. The strongest annual value expansion occurred in 2025 at 5.9%, while the slowest was 4.3% in 2021. Product-mix upgrading remained the principal value-growth multiplier because clinical robotic systems command substantially higher ASPs than manual walkers and basic FES devices.
Forecast Market Outlook (2025-2032)
Forecast value growth averages 6.0% annually through 2032, compared with modeled unit growth of 5.0%. Annual unit demand rises to approximately 66,085 devices by 2032, while blended revenue per unit increases toward USD 8,900 as robotics, service, software and sensor-enabled systems expand their contribution. Reimbursement for personal exoskeletons, hospital modernization and APAC rehabilitation investment support forecast closure, while capital-cost pressure prevents a substantially higher market-wide CAGR.
CHAPTER 5 - Market Data
Market Breakdown
The Global Gait Trainer Market is shifting toward higher-value robotic, sensor-enabled and home-capable systems. For CEOs and investors, the key question is not only unit growth, but how quickly the product mix transitions toward technology, software and recurring service revenue.
Year | Market Size (USD Mn) | YoY Growth (%) | Unit Volume | Blended ASP (USD/unit) | Robotic and Exoskeleton Value Mix (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $302 Mn | +- | 37,700 | 8,011 | Forecast | |
| 2021 | $315 Mn | +4.3% | 39,100 | 8,056 | Forecast | |
| 2022 | $332 Mn | +5.4% | 40,800 | 8,137 | Forecast | |
| 2023 | $351 Mn | +5.7% | 42,800 | 8,201 | Forecast | |
| 2024 | $370 Mn | +5.4% | 44,730 | 8,272 | Forecast | |
| 2025 | $392 Mn | +5.9% | 46,966 | 8,346 | Forecast | |
| 2026 | $416 Mn | +6.1% | 49,314 | 8,436 | Forecast | |
| 2027 | $440 Mn | +5.8% | 51,780 | 8,497 | Forecast | |
| 2028 | $467 Mn | +6.1% | 54,369 | 8,589 | Forecast | |
| 2029 | $495 Mn | +6.0% | 57,087 | 8,671 | Forecast | |
| 2030 | $525 Mn | +6.1% | 59,941 | 8,759 | Forecast | |
| 2031 | $556 Mn | +5.9% | 62,938 | 8,834 | Forecast | |
| 2032 | $589 Mn | +5.9% | 66,085 | 8,913 | Forecast |
Unit Volume
46,966 units, 2025, global. Installed-base replacement and greenfield procurement provide recurring demand. DIH reported more than 4,500 rehabilitation and research devices installed across its global footprint, illustrating the replacement and service base available to technology suppliers.
Blended ASP
USD 8,346 per unit, 2025, global. Average economics are highly mix-sensitive because manual systems and premium powered exoskeletons occupy very different price bands. CMS used a current multi-manufacturer powered-exoskeleton price of USD 125,951.75 when establishing the 2024 K1007 fee schedule.
Robotic and Exoskeleton Value Mix
55%, 2025, global. High-value robotic systems contribute disproportionately to revenue relative to units. FDA's powered-exoskeleton product-code database currently identifies multiple cleared manufacturers, including CYBERDYNE, Ekso Bionics, Lifeward, Samsung, ExoAtlet and Wandercraft.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Technology
Product Type
Care Setting
End User
Disease Area
Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Product Type
Product economics are bifurcated between high-volume manual gait walkers and lower-volume, high-value robotic equipment. Robotic and Exoskeleton Gait Trainers represent the strongest value pool because clinical systems can command six-figure pricing while supporting software, maintenance and training revenue. Manual systems remain strategically important for pediatric, home-care and cost-sensitive rehabilitation environments.
Technology
Technology is the fastest-evolving dimension as suppliers combine robotics, sensors, real-time gait analytics, FES and adaptive software. Sensor, AI and FES Integration is expected to gain the most strategic importance because it enables measurable outcomes, treatment personalization, remote monitoring and recurring software revenue while supporting migration from institution-only rehabilitation toward connected home and community use.
CHAPTER 7 - Regional Analysis
Regional Analysis
Global demand remains concentrated in North America and Europe, while Asia-Pacific provides the strongest incremental growth opportunity. North America's leading position reflects advanced rehabilitation infrastructure and payer support, whereas APAC expansion is driven by hospital capacity, aging populations and rising neurological rehabilitation needs.
Regional Ranking
North America, 1st
Regional Share vs Global (North America)
37.8%
Global CAGR (2025-2032)
6.0%
Regional Ranking
North America, 1st
Regional Share vs Global (North America)
37.8%
Global CAGR (2025-2032)
6.0%
Regional Analysis (Current Year)
Regional Analysis Comparison
Market Position
North America ranks first with approximately USD 148 Mn of 2025 market value, supported by high clinical-robotics penetration and US reimbursement pathways for powered personal exoskeletons.
Growth Advantage
Asia-Pacific is modeled at 6.6% CAGR versus 5.4% for Europe, giving APAC the strongest regional growth profile as rehabilitation infrastructure expands in China, India, Japan and neighboring healthcare markets.
Competitive Strengths
North America combines reimbursement, specialist rehabilitation networks and domestic OEM capacity; CMS set K1007's 2024 purchase fee at USD 91,031.93, directly improving premium personal-exoskeleton affordability.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the Global Gait Trainer Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Expanding Global Rehabilitation Need
- WHO estimates more than 50% unmet rehabilitation need in some low- and middle-income countries (2024, global), creating long-term whitespace for lower-cost gait training and scalable therapist-support technologies.
- Approximately 86 million people require rehabilitation because of stroke (2023, global), sustaining demand for repetitive gait retraining, body-weight support and robotics in post-stroke recovery pathways.
- The World Health Assembly adopted a rehabilitation-strengthening resolution with 20 country cosponsors (2023, global), increasing the policy legitimacy of rehabilitation investment within universal health coverage.
Population Aging and Mobility Impairment
- By 2030, 1 in 6 people globally will be aged 60 or older, increasing exposure to stroke, falls, Parkinsonian gait impairment and post-surgical rehabilitation requirements.
- The share of the global population aged over 60 is projected to move from 12% in 2015 to 22% in 2050, structurally increasing demand for mobility-support interventions.
- WHO notes that 80% of older people will live in low- and middle-income countries by 2050, strengthening the investment case for lower-cost modular gait systems and localized distribution.
Robotics, Sensors and Clinical Automation
- DIH reports 1,500+ medical device registrations across 75 countries (2025), demonstrating the regulatory footprint required to commercialize advanced rehabilitation platforms at scale.
- Tyromotion reports 8,500+ devices deployed across more than 72 countries, indicating broad international acceptance of technology-assisted rehabilitation and specialist distributor networks.
- FDA classifies powered lower-extremity exoskeletons as Class II medical devices under 21 CFR 890.3480, providing a defined US regulatory route for new robotic systems.
Market Challenges
High Capital Cost and Budget Friction
- The large gap between manual equipment and six-figure robotics forces buyers to evaluate utilization and patient throughput carefully; the USD 91,031.93 Medicare K1007 fee amount (2024, US) illustrates the capital intensity of reimbursable personal systems.
- DIH reported USD 62.9 million FY2025 revenue versus USD 64.5 million FY2024, with management attributing the decrease partly to lower average selling price product mix, highlighting supplier sensitivity to procurement mix.
- Ekso Bionics' revenue decreased to USD 12.8 million in 2025 from USD 17.9 million in 2024, demonstrating that advanced-device adoption can remain lumpy despite strong structural demand.
Rehabilitation Workforce Constraints
- Advanced systems require therapist training, workflow redesign and equipment utilization discipline; WHO identifies workforce shortages as a major global rehabilitation-access constraint.
- Tyromotion supports users through a network spanning 45+ distributors and 72+ countries, illustrating the scale of clinical training and technical-service infrastructure required for international deployment.
- Restorative Therapies operates across 20+ countries in addition to the United States and provides dedicated clinical and technical support, showing that post-sale education is a material operating requirement.
Regulatory Fragmentation and Evidence Requirements
- FDA recognizes standards including IEC 80601-2-78 for rehabilitation medical robots, increasing engineering, safety and documentation requirements before commercialization.
- The EU MDR transition for legacy medical devices runs to 31 December 2027 or 31 December 2028 depending on risk class, requiring manufacturers to manage certification and surveillance transitions.
- EUDAMED UDI/device registration became mandatory for relevant users from 28 May 2026, adding traceability and data-management obligations for manufacturers selling in the EU.
Market Opportunities
Reimbursed Home and Community Exoskeletons
- Manufacturers can combine device revenue with fitting, training, service and support; CMS based K1007 economics on prices from multiple powered-exoskeleton manufacturers, supporting category-level competition rather than a single-product pathway.
- Lifeward reported USD 8.5 million ReWalk Personal exoskeleton revenue in 2025, showing that reimbursed personal mobility can form a measurable commercial revenue pool.
- FDA cleared the ReWalk 7 Personal Exoskeleton on 12 March 2025, illustrating continued product renewal and the potential for next-generation home-use systems.
Asia-Pacific Rehabilitation Infrastructure Expansion
- Future Market Insights identifies Asia-Pacific as the fastest-growing gait trainer region, supported by healthcare infrastructure development and rising rehabilitation awareness.
- CYBERDYNE, founded in 2004 in Japan, has developed international commercialization around HAL, demonstrating that APAC can support globally relevant rehabilitation-robotics innovation.
- WHO expects 80% of the world's older population to live in low- and middle-income countries by 2050, reinforcing the need for scalable product architectures suitable for emerging healthcare systems.
Software, Data and Recurring Service Revenue
- Ekso reported USD 3.1 million deferred revenue at year-end 2025, showing how maintenance, subscriptions and contracted support create visibility beyond equipment shipment cycles.
- Tyromotion's connected portfolio includes the Maya therapy platform alongside robotics, supporting a shift toward digital workflow integration across an installed base of 8,500+ devices.
- zebris is investing EUR 5.4 million in a new 2,700-square-meter facility, including development, production and training infrastructure, illustrating continued investment in gait measurement and therapy technology.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market is moderately fragmented: premium robotics requires regulatory approvals, clinical evidence, engineering capability and service infrastructure, while manual gait trainers remain accessible to a broader tail of specialist medical-equipment manufacturers.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
DIH Medical Group (Hocoma) | - | Volketswil, Switzerland | 1996 | Robotic gait rehabilitation, body-weight support, instrumented gait platforms |
Lifeward Ltd. | - | Marlborough, Massachusetts, USA | 2001 | Personal exoskeletons, rehabilitation exoskeletons, anti-gravity systems, FES |
Ekso Bionics Holdings, Inc. | - | San Rafael, California, USA | 2005 | Clinical and personal powered exoskeletons |
CYBERDYNE, Inc. | - | Tsukuba, Ibaraki, Japan | 2004 | HAL wearable cyborg and cybernics rehabilitation systems |
Ottobock SE & Co. KGaA | - | Duderstadt, Germany | 1919 | Mobility, neuro-orthotics, exoskeletons and gait-support products |
Rifton Equipment | - | Rifton, New York, USA | 1977 | Pediatric and adult adaptive gait trainers |
Biodex Medical Systems, Inc. | - | Shirley, New York, USA | 1970 | Instrumented gait treadmills, unweighing and rehabilitation systems |
Tyromotion GmbH | - | Graz, Austria | 2007 | Robotic gait training and technology-assisted neurorehabilitation |
zebris Medical GmbH | - | Isny im Allgäu, Germany | 1987 | Instrumented gait analysis, treadmill-based gait training and biomechanics |
Restorative Therapies, Inc. | - | Nottingham, Maryland, USA | - | Integrated FES systems for neurorehabilitation and mobility |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Analysis Covered
Market Share Analysis:
Compares in-scope revenue scale and competitive positioning across supplier tiers.
Cross Comparison Matrix:
Benchmarks device footprint, approvals, revenue growth and recurring services globally.
SWOT Analysis:
Evaluates technology moats, channel strengths, reimbursement exposure and execution risks.
Pricing Strategy Analysis:
Assesses manual, treadmill, robotic and personal-exoskeleton pricing architecture globally.
Company Profiles:
Reviews portfolios, geographic reach, technology platforms and commercialization priorities systematically.
CHAPTER 10 - REPORT TOC
Table of Contents
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Rehabilitation device regulatory database review
- Gait trainer product portfolio mapping
- Public company revenue disclosure analysis
- Hospital rehabilitation demand indicator review
Primary Research
- Rehabilitation department heads interviewed
- Physical therapy directors interviewed
- Medical device distributors interviewed
- Rehabilitation procurement managers interviewed
Validation and Triangulation
- 312 respondent evidence cross-check
- OEM revenue reconciled with volumes
- ASP benchmarks tested across technologies
- Demand estimates reconciled by setting
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
No adjacent reports found.
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals